Latest / Boardroom Conversations with Fexingo: CEOs, Strategy, and Corporate Leadership Explained
How the Novo Nordisk Board Rode a Weight-Loss Wave
In this episode of Boardroom Conversations, Lucas and Luna examine how Novo Nordisk's board managed the explosive rise of Wegovy and Ozempic, turning a Danish pharma into Europe's most valuable company. They trace the board's early bet on obesity as a chronic condition, its handling of supply shortages and patent cliffs, and the strategic decisions around capacity investment and competition from Eli Lilly. They also explore how the board navigated pricing pressure, regulatory scrutiny, and the cultural shift within a company suddenly at the center of a global health craze…
The skinny
The skinny isn't ready yet — notes appear once the transcript is processed.